title: Antierythrocyte autoantibody formation after therapy with interleukin-2 and gamma-interferon.
abstract: The cardiovascular, renal, pulmonary, and dermatologic toxicities of interleukin-2 (IL-2) and gamma-interferon (IFN) are well described. However, autoimmune toxicities have only recently been noticed. The authors report the development of warm autoantibodies against erythrocytes in a patient receiving IL-2 (3.75 x 10(6) cetus units/m2 intravenous bolus three times per week) and gamma-IFN (0.1 mg/m2 subcutaneously three times per week) for metastatic renal cell carcinoma. Other potential causes of autoantibody formation, such as drugs, infection, and collagen vascular disease, were excluded. Both gamma-IFN and IL-2 have the potential to trigger or exacerbate autoimmunity due to either aberrant expression of restricted antigens or inhibition of normal cellular immune suppressor mechanisms.
authors.affiliation: Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111.
authors.forename: R
authors.initials: R
authors.lastname: Perez
authors.forename: K
authors.initials: K
authors.lastname: Padavic
authors.forename: R
authors.initials: R
authors.lastname: Krigel
authors.forename: L
authors.initials: L
authors.lastname: Weiner
mesh_terms: D001323:Autoantibodies / Q000032:analysis*; D002292:Carcinoma, Renal Cell / Q000276:immunology* / Q000556:secondary / Q000628:therapy*; D004912:Erythrocytes / Q000276:immunology*; D005260:Female; D006801:Humans; D007371:Interferon-gamma / Q000627:therapeutic use*; D007376:Interleukin-2 / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000276:immunology* / Q000628:therapy*; D008875:Middle Aged
chemical_list: D001323:Autoantibodies; D007376:Interleukin-2; D007371:Interferon-gamma